Edwards lifesciences reports second quarter results

Irvine, calif.--(business wire)--edwards lifesciences (nyse: ew) today reported financial results for the quarter ended june 30, 2025. recent highlights q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups q2 tavr sales grew 8.9%; constant currency1 sales grew 7.8% q2 tmtt sales reached $134.5 million or $133.0 million adjusted1, driven by pascal and evoque q2 eps of $0.572; adjusted1 eps of $0.67 sapien platform is only tavr approved for asymptomati.
EW Ratings Summary
EW Quant Ranking